| Analysis of 50 cases of severe adverse reactions associated with immune checkpoint inhibitors in the real world |
| Received:June 11, 2020 Revised:November 13, 2020 Click here to download the full text |
| Citation of this paper:AI Luo-yan,YU Yi-yi,LIN Jin-yi,LIU Chun-hong,HU Jie,GAO Di,WU Wei,JIN Hang,ZHAO Lin,SUN Ying,WANG Yan,LI Qian,CUI Yue-hong,XU Bei,LIU Tian-shu.Analysis of 50 cases of severe adverse reactions associated with immune checkpoint inhibitors in the real world[J].Chinese Journal of Clinical Medicine,2020,27(6):938-944 |
| Hits: 3323 |
| Download times: 1840 |
| Author Name | Affiliation | E-mail | | AI Luo-yan | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | YU Yi-yi | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LIN Jin-yi | Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LIU Chun-hong | Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | HU Jie | Department of Respiratory, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | GAO Di | Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WU Wei | Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | JIN Hang | Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | ZHAO Lin | Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | SUN Ying | Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WANG Yan | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LI Qian | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CUI Yue-hong | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | XU Bei | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LIU Tian-shu | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China | liu.tianshu@zs-hospital.sh.cn |
|
| Abstract:Objective: To explore the general situation of severe immune-related adverse events (irSAEs) in the real world. Methods: A total of 50 patients who were diagnosed with serious irSAEs in Zhongshan Hospital, Fudan University between June 2018 and June 2020 were included. Clinical data including the basic data, drug use, median onset time, laboratory examination, treatment, and prognosis were recorded and analyzed.Results: The spectrum of severe irSAEs included myocarditis, hepatitis, colitis, pneumonitis, primary adrenal insufficiency, diabetes, and nervous system adverse events. The median age of patients was 61 years, 66% of patients were male, and the median time of onset was 6 weeks after starting immune checkpoint inhibitors (ICIs). Steroids were administered in 45 patients (90%). After intensive treatments, 39 patients (77.5%) recovered, and 11 patients (22.5%) had the outcome of death. Main causes of death were myocarditis and hepatitis. Compared with those recovered, patients who died received higher doses of glucocorticoids ([267.27±190.22]mg vs[105.38±145.49] mg, P=0.021), and more patients were additionally given another immunosuppressant (10.0% vs 6.0%, P=0.009). In this study, 19 patients were diagnosed with myocarditis. Different from other irAEs usually affecting one organ, myocarditis was more prone to be concurrent with other system irAEs such as hepatitis, myositis, and thyroiditis. Patients who died from myocarditis had higher NT-proBNP (12 844 vs 479.7 pg/mL, P=0.000 6) and cTnT levels (0.928 vs 0.233 ng/mL, P=0.006 4) than those recovered from myocarditis. But no statistical significance existed between the two groups for left ventricular ejection fraction (62.75% vs 65.11%, P=0.348 2).Conclusions: Severe irSAEs affect key organs including heart, liver, lung, and intestine. The prognosis of irSAEs is poor even if high-dose glucocorticoids were administrated. |
| keywords:immune checkpoint inhibitors severe immune-related adverse events real-world myocarditis |
| HTML View Full Text View/Add Comment Download reader |
|
|
|